Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disease of unknown etiology with multisystem involvement. The main organs affected are the skin, joints, kidneys, lungs, nervous system and blood, among others, with varying severity. There is currently no treatment or cure definitive etiologic LES, so treatment is aimed at manifestations of the same disease. The overall objective of treatment is to control the disease activity and prevent as far as possible outbreaks. Belimumab is a human monoclonal antibody that binds specifically to the soluble form of the protein stimulating human B cells (Blyss) blocking the binding of the receptor to its respective B cells was approved by the Agency European Medicines July 2011 as adjunctive therapy in adult patients with SLE active with positive autoantibodies with a high degree of disease activity (p. ex. antiDNAdc positive and low complement) despite standard treatment. Objective: To review the efficacy, safety and efficiency in the belimumab treatment of SLE in adults compared to any alternative treatment, including placebo.
Systemic Lupus Erythematosus; Belimumab; Clinical Trial
Comitè d'Avaluació de Medicaments d'Utilització Hospitalària (CAMUH). Belimumab (Benlysta®) per al tractament del lupus eritematós sistèmic. Barcelona: Agència d‟Informació, Avaluació i Qualitat en Salut; 2013.
Use this identifier for quote and/or link this documenthttps://hdl.handle.net/11351/846
This item appears in following collections
The following license files are associated with this item: